Omnia Health Solutions Enrolls First Patient in BEACON, a Real-World Study of GLP-1 Use and Lifestyle Support

AUSTIN, TX — September 16, 2025 — Omnia Health Solutions, LLC (“Omnia”), a real-world outcomes research company, today announced that the first patient has enrolled in BEACON, its decentralized, longitudinal study evaluating the real-world effectiveness of GLP-1 therapies combined with lifestyle intervention. The milestone marks the official launch of a national effort to understand how patients succeed on GLP-1s long-term, outside the controlled trial setting.

BEACON integrates electronic health record (EHR) data, patient-reported outcomes, and digital engagement metrics from the Mayo Clinic Diet platform. Using advanced analytics, the study will identify patient subtypes, predict treatment success, and generate insights to inform clinical decisions and new indications.

“Enrolling our first patient is a meaningful proof point that our patient-mediated model works,” said Laura Kelso, COO and co-founder of Omnia. “By enabling patients to directly link their EHRs, we’re delivering high-quality, comprehensive clinical data at scale, creating a robust foundation that traditional research often lacks.”

Recognizing the importance of the patient-physician relationship, Omnia is partnering with primary care, endocrinology, and weight management practices across the country to refer patients into the study. Omnia has also partnered with the Obesity Medicine Association (OMA) to offer CME-accredited education and tools to support physicians and enhance care.

In parallel, Omnia is elevating the patient experience with tools that extend beyond the prescription. Study participants receive complimentary access to the Mayo Clinic Diet digital platform, including lifestyle coaching, nutrition guidance, and behavior support. Combined with quarterly follow-ups, Omnia’s model drives better adherence and long-term success with GLP-1 therapies.

About Omnia Health SolutionsOmnia Health Solutions is a real-world outcomes research company focused on obesity management and GLP-1 therapies. Omnia's innovative model integrates physician and patient support with longitudinal data, delivering the insights needed to optimize treatment, support access, and improve long-term success of next-generation treatments.